Celularity Inc., a leader in regenerative medicine, recently announced a transformative strategic partnership with NexGel to commercialize its placental-derived biomaterials portfolio.
Under the terms of the agreement, Celularity is granting NexGel an exclusive license to its commercial-stage biomaterials—a suite of six products used in tendon repair, skin grafts and bone growth. The transaction includes a $15 million upfront payment and up to $20 million in future milestones, with a closing date set for no later than April 15.
A critical component of the deal ensures that New Jersey remains the production hub for these advanced medical technologies. Celularity will act as the exclusive manufacturer for the licensed products at its 150,000-square-foot, FDA-compliant facility in Florham Park.
This arrangement provides Celularity with a steady stream of manufacturing revenue and service margins while maintaining the high-tech jobs tied to its vertically integrated infrastructure.
“This partnership represents a disciplined step forward in strengthening our capital position while sharpening our focus on longevity medicine,” Dr. Robert Hariri, chairman and CEO of Celularity said. “We are monetizing commercial infrastructure… and retaining long-term economic participation through manufacturing and royalties.”
The deal triggers a strategic “organizational realignment” for the company. By offloading the commercial and sales responsibilities of the biomaterials business to NexGel, Celularity is redirecting its internal resources toward its high-value therapeutic pipeline.
The company’s future is now firmly rooted in longevity therapeutics, specifically targeting:
- Cellular Senescence: Addressing “zombie cells” that contribute to aging.
- Tissue Degeneration: Using placental-derived cells to repair age-related damage.
- Chronic Inflammation: Tackling the underlying biological drivers of systemic decline.
As part of this shift, some Celularity personnel associated with the biomaterials division are expected to transition to NexGel, allowing Celularity to reduce its overall operating expenses and focus on clinical-stage cellular therapies.
